This trial is active, not recruiting.

Condition allergic conjunctivitis
Treatment tacrolimus 0.03% ointment (protopic)
Phase phase 2
Sponsor Assaf-Harofeh Medical Center
Trial identifier NCT00443105, 20050321


The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model single group assignment
Masking open label
Primary purpose treatment

Eligibility Criteria

Male or female participants at least 5 years old.

Inclusion Criteria: - Subjects included if they were > 5 years old and suffered from intractable allergic conjunctivitis Exclusion Criteria: - pregnancy or breastfeeding,history of herpetic eye disease,transplant patients concomitant administration of drugs inhibiting cytochrome CYP3A4, hypersensitivity to macrolides

Additional Information

Principal investigator David Zadok, MD
Trial information was received from ClinicalTrials.gov and was last updated in March 2007.
Information provided to ClinicalTrials.gov by Assaf-Harofeh Medical Center.